Brokers Offer Predictions for KROS Q3 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROSFree Report) – Research analysts at Wedbush issued their Q3 2024 earnings per share estimates for shares of Keros Therapeutics in a research report issued on Monday, November 4th. Wedbush analyst Y. Zhong expects that the company will earn ($1.31) per share for the quarter. Wedbush has a “Outperform” rating and a $84.00 price objective on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.90) per share. Wedbush also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($5.14) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.25) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.57) EPS and FY2028 earnings at ($4.66) EPS.

Keros Therapeutics (NASDAQ:KROSGet Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.33) earnings per share.

Other analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday. Bank of America decreased their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Scotiabank assumed coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price for the company. Finally, Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday. They issued a “buy” rating for the company. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $88.89.

Check Out Our Latest Stock Report on KROS

Keros Therapeutics Stock Up 1.1 %

KROS opened at $67.17 on Thursday. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00. The company has a fifty day simple moving average of $57.30 and a 200 day simple moving average of $51.99. The stock has a market cap of $2.52 billion, a P/E ratio of -13.09 and a beta of 1.23.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 22.90% of the stock is currently owned by insiders.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. KBC Group NV lifted its stake in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics during the 3rd quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics during the 2nd quarter valued at approximately $128,000. Finally, Ameritas Investment Partners Inc. lifted its stake in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Featured Stories

Earnings History and Estimates for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.